Voyager Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €58.21M -22.2% -€135.18M -∞% -232.3% -2.3 pp -€114.38M +15.6% -196.5% -0.64 pp
    (estimated) €74.80M +23.5% N/A N/A -€98.98M +110.0% -132.3% -0.55 pp
    (estimated) €60.54M +14.0% N/A N/A -€47.13M -43.7% -77.8% +0.80 pp
    (estimated) €53.13M +107.1% -€85.28M -19.2% -160.5% +2.5 pp -€83.69M -22.3% -157.5% +2.6 pp
    (estimated) €25.66M -62.4% -€105.51M +90.3% -411.2% -3.3 pp -€107.67M +970.7% -419.6% -4.0 pp
    €68.24M -68.0% -€55.44M -149.1% -81.3% -1.3 pp -€10.06M -114.5% -14.7% -0.47 pp
    €213.24M +511.2% €112.87M -385.1% 52.9% +1.7 pp €69.24M -910.3% 32.5% +0.57 pp
    €34.89M +9.3% -€39.58M -29.7% -113.4% +0.63 pp -€8.54M -80.7% -24.5% +1.1 pp
    €31.91M -78.1% -€56.32M -279.7% -176.5% -2.0 pp -€44.28M -38.6% -138.8% -0.89 pp
    €145.96M +63.9% €31.34M -190.0% 21.5% +0.61 pp -€72.18M -250.1% -49.4% -1.0 pp
    €89.04M +1,270.1% -€34.83M -53.8% -39.1% +11 pp €48.09M -586.8% 54.0% +2.1 pp
    €6.50M -24.8% -€75.31M +24.9% -1,158.8% -4.6 pp -€9.88M -79.8% -152.0% +4.1 pp
    €8.64M -28.7% -€60.30M +75.9% -697.6% -4.1 pp -€48.93M +53.2% -566.0% -3.0 pp
    €12.13M -18.0% -€34.28M +35.5% -282.7% -1.1 pp -€31.95M -188.5% -263.4% -5.1 pp
    €14.79M +∞% -€25.31M +81.8% -171.2% -1.7 pp €36.10M -574.0% 244.2% +2.4 pp
    €0.00 +NaN% -€13.92M +112.8% N/A -€7.62M +63.9% N/A
    €0.00 -€6.54M N/A -€4.65M N/A

    Notifications